CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors

• Sjoerd H van der Burg,
• Ramon Arens,
• Hubert Hackl,
• Ziena Abdulrahman,
• Ilina Ehsan,
• Mariette I E van Poelgeest,
• Marij J P Welters,
• Zlatko Trajanoski,
• Peter ten Dijke,
• Saskia J Santegoets,
• Gregor Sturm,
• Francesca Finotello,
• Chantal L Duurland,
• Nikki M Loof,
• Tom H Wesselink,
• Sanne Boekestijn,
• Veronique M Braud

Affiliations

Sjoerd H van der Burg

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Ramon Arens

Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

Hubert Hackl

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Ziena Abdulrahman

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Ilina Ehsan

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Mariette I E van Poelgeest

Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands

Marij J P Welters

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Zlatko Trajanoski

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Peter ten Dijke

Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands

Saskia J Santegoets

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Gregor Sturm

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Francesca Finotello

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Chantal L Duurland

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Nikki M Loof

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Tom H Wesselink

Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

Sanne Boekestijn

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Veronique M Braud

Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université Côte d’Azur, UMR7275, 06560 Valbonne, Sophia Antipolis, France